Signia Therapeutics is very proud to announce it has been awarded with the label “French Tech Seed” by a wide and independent evaluation committee composed of representative of local economic environment (Pouss@Lys).
The French Tech Seed is a public fund initiated in July 2018 by French government to support innovative startups in their early development phase. The fund is managed by BPI (Bpifrance), public bank aiming to fund small companies by loans, guarantees and equity. Companies pretending to apply to the French Tech Seed must demonstrate their capabilities to conduct innovative research and turn this research into profitable business.
After several other prizes, it is another recognition of Signia Therapeutics breakthrough strategy in repurposing drugs in medical fields with unmet medical needs, using its proprietary platform based on transcriptomic signatures.